<SEC-DOCUMENT>0001193125-17-038525.txt : 20170210
<SEC-HEADER>0001193125-17-038525.hdr.sgml : 20170210
<ACCEPTANCE-DATETIME>20170210170855
ACCESSION NUMBER:		0001193125-17-038525
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170210
FILED AS OF DATE:		20170210
DATE AS OF CHANGE:		20170210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		17594520

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d306472d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES SECURITIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of February 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-36697 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>177-181 avenue Pierre Brossolette
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92120 Montrouge France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9746;&nbsp;Form 20-F&nbsp;&#9744;&nbsp;Form 40-F </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&#9744; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST</U></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February 10, 2017.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: February&nbsp;10, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Chief Operating Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g306472g44a18.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Press Release </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Montrouge, France, February&nbsp;10, 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>DBV to Present Data at the 2017 AAAAI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Meeting Highlighting the Therapeutic </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Potential of EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eight abstracts, including detailed two-year follow-up data to the VIPES Phase IIb trial supporting the long-term efficacy and safety of Viaskin Peanut for
the treatment of peanut allergy, will be presented during the meeting </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies (Euronext: DBV &#150; ISIN: FR0010417345&#151;Nasdaq Stock Market:
DBVT), today announced that eight abstracts, seven of which will highlight data from the company&#146;s Viaskin technology platform, were accepted for oral and poster presentation at the 2017 American Academy of Allergy, Asthma&nbsp;&amp; Immunology
(AAAAI) Annual Meeting in Atlanta, Georgia, March&nbsp;3-6, 2017. These abstracts became available on the AAAAI meeting website at 9:30 AM CT on February&nbsp;10 <U>http://annualmeeting.aaaai.org/</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Detailed results from the OLFUS-VIPES trial, which followed patients for a total of 36 months, will be presented during the Late Breaking Oral Abstract
Session on Sunday, March&nbsp;5. Topline results from OLFUS-VIPES, which evaluated the long-term efficacy and safety of Viaskin Peanut for the treatment of peanut-allergic children, were previously announced in October 2016. Viaskin Peanut is the
company&#146;s lead product candidate based on its proprietary EPIT platform, which aims to deliver biologically active compounds to the immune system through the skin, and is currently being evaluated in a global, pivotal Phase III program in
peanut-allergic children 4 to 11 years of age. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&#147;The long-term clinical data we are presenting at AAAAI provide further insight into the promise
of Viaskin Peanut as a potential treatment option for peanut-allergic children,&#148; said </I><B><I>Dr.&nbsp;Lucia Septi&eacute;n</I></B><I>, Chief Medical Officer of DBV Technologies. &#147;These detailed results, combined with pre-clinical data
that will be presented at the meeting, also underscore the tremendous potential of EPIT to help address a wide range of unmet medical needs.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional abstracts to be presented at the meeting include two pre-clinical studies, which tested the therapeutic potential of EPIT in type 1 diabetes and in
the vaccination against respiratory syncytial virus (RSV). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selected abstracts of interest: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Peanut Allergy Data </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Efficacy and Safety of Long-Term Epicutaneous Immunotherapy (EPIT) Treatment of Peanut Allergy with
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut: Results of the Two-Year Extension of the VIPES Phase IIb Clinical</I> </P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g306472g24k99.gif" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"><I>Trial&#148; </I>will be presented by Dr.&nbsp;Wayne&nbsp;G. Shreffler, Division of Allergy and Immunology, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School.<I> </I> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Oral Presentation</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 3611 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> L7 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title:</I> Late Breaking Oral Abstract Session: Clinical/Translational Science </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Sunday, March&nbsp;5 / 2:15 PM to 2:30 PM </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FARRP (</B><B><I>Food Allergy
Research&nbsp;&amp; Resource Program</I></B><B>) Data </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Increasing Clinical Peanut Thresholds Through Immunotherapy: Quantitative Assessment of the Safety Benefits Associated with Achieving a 300 or 1000 mg Peanut Protein Threshold&#148;</I> will be presented by
Dr.&nbsp;Joseph&nbsp;L. Baumert, Food Allergy Research and Resource Program, University of Nebraska-Lincoln. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Oral Presentation</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 3604 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 561 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title:</I> Immunotherapy for Food Allergy </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Sunday, March&nbsp;5 / 2:45 PM to 3:00 PM </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RSV Data </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Preclinical evaluation of a novel non-invasive epicutaneous vaccine against respiratory syncytial virus&#148;</I> will be presented by Dr.&nbsp;Pierre-Louis Herv&eacute;, DBV Technologies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 3802 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 589 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title: </I>Immunotherapy: How to Reprogram the Immune System </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Sunday, March&nbsp;5 / 4:45 PM to 6:15 PM </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type 1 Diabetes Data </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;EPIT decreases T1D incidence in sensitized non obese diabetic mice: a likely bystander effect of EPIT-induced Tregs&#148;</I> will be presented by Dr.&nbsp;Benjamin Pelletier, DBV Technologies.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Session</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 2203 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 52 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title: </I>Immune Modulation </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Saturday, March&nbsp;4 / 9:45 AM to 10:45 AM </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EPIT Mechanism of Action Research </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Treatment of eosinophilic gastritis by Epicutaneous Immunotherapy (EPIT) in peanut allergic piglets&#148;</I> will be presented by Dr.&nbsp;Lucie Mondoulet, DBV Technologies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Session</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 2208 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 153 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title:</I> Eosinophilic Gastrointestinal Disorders and Non-IgE Mediated Food Allergy </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g306472g24k99.gif" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Saturday, March&nbsp;4 / 9:45 AM to 10:45 AM </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Allergen Capture by DCs during Epicutaneous Immunotherapy is Enhanced by Modulating the Dose and the Surface Area of the Patch&#148;</I> will be presented by Dr.&nbsp;Sophie Wavrin, DBV Technologies.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Session</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 4210 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 806 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title: </I>Allergen Extracts and Other Forms of Immunotherapy </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Monday, March&nbsp;6 / 9:45 AM to 10:45 AM </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Crucial Role of Langerhans Cells in Allergen Uptake and Regulatory T Cell Induction in Epicutaneous Immunotherapy&#148;</I> will be presented by Dr.&nbsp;Vincent Dioszeghy, DBV Technologies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Session</I> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 4210 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 805 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title: </I>Allergen Extracts and Other Forms of Immunotherapy </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Monday, March&nbsp;6 / 9:45 AM to 10:45 AM </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>&#147;Foxp3+ CD62L+ Tregs induced by EPIT have the potency to suppress effector T cells proliferation in specific and bystander conditions&#148;</I> will be presented by Dr.&nbsp;Benjamin Pelletier, DBV Technologies.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Number:</I> 4210 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Poster Number:</I> 801 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Session Title: </I>Allergen Extracts and Other Forms of Immunotherapy </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Date/Time:</I> Monday, March&nbsp;6 / 9:45 AM to 10:45 AM </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Full data will be shared following embargo lift;
at the time the studies are presented. All abstracts are available online at <U>http://annualmeeting.aaaai.org/</U>, and will also be published in a supplement to the February <I>Journal of Allergy and Clinical Immunology (JACI</I>) at
<U>http://www.jacionline.org/</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the PEPITES Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Peanut EPIT Efficacy and Safety Study (PEPITES) is a global, pivotal, double-blinded, placebo-controlled Phase III trial designed to evaluate the safety
and efficacy of Viaskin Peanut 250 &micro;g in children ages four to 11 years. During PEPITES, patients&#146; response will be assessed using a double-blind, placebo controlled food challenge (DBPCFC). Patients are randomized 2:1 to receive either
Viaskin Peanut 250 &micro;g or placebo for 12 months. The primary endpoint is based on a responder analysis after 12 months of treatment with Viaskin Peanut 250 &micro;g. For patients with a baseline peanut protein eliciting dose (ED) equal to or
less than 10 mg, a responder is defined as a patient with a peanut protein ED equal to or greater than 300 mg of peanut protein after 12 months of treatment. For subjects with a baseline ED greater than 10 mg, a responder is defined as a patient
with a peanut protein ED equal to or greater than 1,000 mg of peanut protein after 12 months of treatment. As a secondary efficacy endpoint, Cumulative Reactive Dose (CRD), will also be used in PEPITES to establish the total quantity of peanut
protein that triggers patient reactions at month 12 of active treatment versus placebo. Serological markers will also be measured at baseline, 3, 6, and 12 months in order to characterize the immunological changes in patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the completion of PEPITES, all patients are eligible to rollover into PEOPLE, a long-term, open-label extension study of Viaskin Peanut 250
&micro;g. In the PEOPLE study, patients who were randomized to active treatment during PEPITES will receive Viaskin&nbsp;Peanut 250 &micro;g for two additional years; patients who were previously receiving placebo during PEPITES will be treated with
Viaskin Peanut 250 &micro;g for three years. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g306472g24k99.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients enrolling in the PEOPLE study will remain blinded to their respective treatment group in PEPITES until the PEPITES
study results become publicly available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the REALISE Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REALISE is a multicenter, randomized, double-blind, placebo-controlled Phase III study designed to assess the use of Viaskin Peanut 250 &micro;g in routine
medical practice and generate safety data after six months of blinded treatment in patients four to 11 years of age. At the six-month time point, patients in both the placebo and active arms will be able to opt into an open-label portion of the
study, which will continue monitoring patients for a total of 36 months of active treatment. Exploratory criteria will also include scores from subjects&#146; Food Allergy Quality of Life Questionnaire (FAQLQ) and the Food Allergy Independent
Measure (FAIM), as well as the evolution of peanut-specific serological markers over time. The study is expected to be conducted in approximately 30 to 40 centers in North America. No oral food challenges are required in REALISE. Patients in the
study will be selected based on a well-documented medical history of IgE-mediated reactions to peanut, including children with a history of severe anaphylaxis, as well as analyses of peanut-specific immunological markers. During the first six months
of trial, patients will be randomized 3:1 active versus placebo. Key assessments of safety parameters will include treatment-emergent adverse events observed in both the placebo and active treatment groups after the initial 6 months, which will
continue to be monitored during the open-label portion of the study. DBV intends to enroll approximately 335 subjects in REALISE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the
OLFUS-VIPES Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OLFUS-VIPES (Open-Label Follow-Up Study-Viaskin Peanut&#146;s Efficacy and Safety), or OLFUS, enrolled 171 subjects who had
previously received either placebo or one of three 12-month dose regimens administered during VIPES. During the first year of OLFUS, patients were to receive a daily application of Viaskin Peanut 50 &micro;g or Viaskin Peanut 100 &micro;g or Viaskin
Peanut 250 &micro;g for 12 months. According to a study protocol change implemented in March 2014, all patients were switched to receive Viaskin Peanut 250 &micro;g during OLFUS. All patients in OLFUS maintained a peanut-free diet during the study.
Baseline response levels in OLFUS were based on the results of the last double-blind, placebo controlled food challenge (DBPCFC) in VIPES, and adjusted by the number of patients enrolling in OLFUS. Responders in the OLFUS trial were defined as
subjects with a peanut protein eliciting dose equal to or greater than 1,000 mg peanut protein or with a greater than 10-fold increase of the eliciting dose compared to their baseline eliciting dose observed in the VIPES study. Patients enrolled in
OLFUS who received placebo in VIPES were analyzed separately from subjects who initially received Viaskin Peanut. At month 24 in OLFUS, patients who were unresponsive to a cumulative dose above 1,440 mg were eligible to discontinue study drug for
two months while maintaining a peanut-free diet. Patients who opted to enter into this additional period performed a DBPCFC at month-26 to assess durability of response. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV Technologies</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, DBV&#146;s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV&#146;s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies,
please visit our website: www.dbv-technologies.com </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g306472g24k99.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements regarding the potential safety and efficacy of Viaskin Peanut and statements
reflecting management&#146;s expectations for clinical development of our product candidates and the commercial potential of our product candidates. These forward-looking statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews
and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of
these risks, uncertainties and other risks can be found in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in
the Company&#146;s Annual Report on Form 20-F for the year ended December&nbsp;31, 2015 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Contact </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Susanna Mesa </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President, Strategy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1&nbsp;212-271-0861 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">susanna.mesa@dbv-technologies.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Andrea Fassacesia, Weber Shandwick </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1&nbsp;212-445-8144
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">afassacesia@webershandwick.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact Europe
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Caroline Carmagnol, Alize RP, Relations Presse </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+33 (0)6 64 18 99 59</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">caroline@alizerp.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g306472g24k99.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g306472g24k99.gif
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MG)2<G'NMUO_W_V.4O6N,I0
M
M
M
M
M
M                     "P     O0)@   (_@ C1!@  $ !  0*#CAPL&!"
M  ,0$&@(@0"! 0$,('0(L>-$  $ (!A <&/! A$Y'DQ <D " ! *=I0H$Z$
MDALM*AQ0P.)#B 8&/'SH$@',F H[YBPXTN=)  (T^@P)P "" P61=AP0,^%!
MDA%J G@Y("S'@@(-5.08MN33E@9UBKAH%(+=A! .:,P@HF"&'W#]SB7H%BE)
M 79ARL0I%BKCB0D)FV0:@&M/Q1EYYNR)\R5> @.QZAS[0(14F72-YK1(LF?"
MB2BM>GT8001&Q9$#","]<<"#L0@M0B Y%[C%F[^=B@1@=JAOH3Z1"D" 5&>
M R1UZB287+A(V]H5_@HP>]:  ;P0"D"H/-*S81$'",0,,+&EQ9<';4N4;_(
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MF4UM2$%K04KYQD*FMO#'+A+Q8'5&59VOGL28//&0?(*7'1))AD7\6:9,7M3
MFJ"03E5EU%:%.DNWR-.7 9BG1O##(0-$I5/GZR#>B'>^R-8SL2N)56(3ZT(
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M%43(5?('*%EA% 2T2A#D6!QA,"DT'(2!:TG1?DE!.'Y5$/2C'G1C6&-Q ![
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M*91<+I$8).*9/M%"[?03HB9F7?5J(3%X\R%+0L)DG_(U^,8X66%,P^%*HR&
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MNA'I8C*:BA0I-)D60A]'I""F>C,4]U(U"#5^ED$$Z2'D8;ORZ$JK T6_0Z*
M#!S4(B4E@C2_DP%I%P$>4*P]$$Y<( $2\.UZ3NY17_F6?_F8G_F:O_E/3UFO
M@5"LF.HU\0/Q WNBK':S*9]=D9XDHC<+XY_-_%4^E44QT<PX%T%.*A/+=!!:
M44UCZA1G]W9 LOI4T]4; =.#,ET<-M9/01'7_F,K * "&6 K/S#]/P!@!5#9
M%0 ":7#TG/_]X!_^XC_^Y*_YP8%(LN7(2?1R?KLES&58L?N.,/%SK;4T'>=Y
MOG22;C&99Q(22MD[  % X    0H2($@ (0 (  I$$ A@0($$ P42, "  ( $
M$S42U*@PPL8#$0L >% Q@(&*%@DD*+D1@ "9#PX*%&"1X\D( 1H*,%@1I$05
M/P#\&*$B XD(!0B(\+"A0X<0(1Q<Q9I5ZU:N7;U^!1M6[%BR9<V>19M6[5JV
M;=V^A1M7[MRT(Q$D4$B@)\0 /4\*S)A!0(8!! QB7 A2:T2),R%L)-#P948"
M.0DV3(  (P"(A@$@_I HDW/CC!P!&%C8^"+C 7T!:#A)4#9#@J@3.@2=4R"$
MEI5]9K29X+'= $,;#VAHL3""QPXG3D18G&'#  5HWA8,8,0/,@*!>$CRX0H,
M$%2S5J6;7OUZ]NW=OX<?7_Y\^ED+"G3=5_0  ]9UTRX(-,\$L@^ Q212"8+B
M$+JMLHV,TXBZD"84R*G[-M),-9P>1 V (#XSZ+(/!<*+L9#T(L ZU@P0P8#"
M(H+H,X882U$A&BN4*+F!4C0@*(D*,V"D^VAZB+$,CE)!!PT\\& !!J9"[[SZ
MIJ2R2BNOQ#)++;?$C[,4#2JHNOM.BR@Y A#H42.L!H!0HJMPU&C,. ^+_M,X
M#I$;<P $"K/0H-(&+',W'8\$0(3+DF.S,-&BDXDWC4Y2*4Y)0:0QT8@".)--
M$B\:JB(;)15AQ@)."B" P03* ((@&J'@"A\ZP J#+6>EM59;;\4U5_D,.^FO
M^S"]Z"^CRJRM5$ <^%%3UMQ$]J2-?)+)69<<JE,VR 1"H  V(XN4VLAV2Q55
M<96;$:<!(J!IH\<*:RTBT69\5T-U/UON6XWZVW;"C?[$;Z-1-? 0/VVU%0&"
M87OHX1.JK-*U88<?ACABB:V\B;\$^@*S -2*ZZ%4CTM%0 ,(&NB L:UT<H !
M#0+P8 L$@M# @ QDRBF!"&Z+T]"&S-266HX4_E*6H%%G&FB 89=ES"=W5S,
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M&I,8T-&RSBVMKX5M;*6WS#!-50?=*T /(A>$?VUM#"4#0 - P-DVS00!JZW
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M1(6 =H4 T=.-&&FNRU ?M4U.AWC3GNA3MHPE4_D>V.B)E=D+D;N(!H)*BTB
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M[!N.D!FC %4/",*KP #7<H!R'N5T-E$-&!'E+930+;7.)+T3$((&0 ,[_J"
M,3"Z#OB!.RC!$&B##A #$,"#&[##"6 9'P@!O/">AF" "J"< @@5Z-*144E8
M6VV(B^Z55Z(6#-0S"L9)ZTJC'QD)R/ <!;P[ZKBHG$F!.&$2DB%G<T9G=:9I
MVC0)@0@53\&J(_'=J5 \6BP JQ"(." 9.=" -[C?=;* 4I& .6@ )_">WV0
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M@0<, += #P/4P" !'."$P$ %F'CB  4@H &+$ @F4 1C68?=7-?%A--8_@6
MY6!. 427$TU##%!!!5)TL!^222JY))--.ODD1P(E()Y, (Q%P%HX 8  5SEY
MY6(#+5#HGE)))>4  "1D0*$'!6S01 -.-/ $BQYX\$.(L]DE%EGGG9563 52
MZ>   4!@6$X0H'>>8>0!5F*A?;K8H X5=' IE)EJNBFGG7KZ:44\BG8= !0P
MP$ !"3:@@@H,)#$@ "DTAR::,3F@VA)$I%8!$PQ0D&%JQPF'6',[FFEEB3G-
M]E8 ?RU*5J0YG3403H56*VV6A]XX0 \:M% !J.&*.RZYY9JKDF..^05 NC0-
MX.("OWJ0009''*%""AML]4$&+F)'J$X+("$$_@@@=,"3 E2!X(('+"R@1 _=
MLJA!$&45H.B+,;6H;($.QI@67A! (.._5@(*P%[,DFBE>I:&H-"Y,<L\,\TU
M/^FQ=8ZQFP#* ="[5PHJ#($#BWNQ57)S W! 1 U%$""C=AK8R54!!J3<' )@
MS<9B3C'&99VS#A:0EHS2\N7C6"RJ2.*H:WU5@!$O'VDSW77;?3?>*[4+($WM
MLGO=@1G\H$$ ^ )ALM%(+P< !QS8F0 !'5<,@%==H:RB=88Q9W9<:$F;DP N
M\F@E7Y]+BUW9U/V(,HD%"-'!RWG+/COMM<\.)  )($  =4 2P-;ONSLVZ%OD
M!9@3SSP:(./3!VSI_E: A$4..;/'%Y"\E8GJ/"5X4,7DK@'@#10]V'L5L%<
M(A)P0@$>W."#[?'+/S_]X0XDP/%F1H!7@ <,9-.HWN66,@TD?->!P $0%0#J
M;>EH8 L?@,PC OPQ95D @@[I^I> S1TO10B P.X P(/I!,!"A=$1!ZS&&DS5
MKX4N?"$,YQ.H&9V/?\IR3 )GU#W1N<@ ^8/+L0*T.Q&,BBR(DHF68B1!E,DD
M4-13UU]Z1!.\#(!G5[H<6'""& U08 $[F%L,PRC&,9*Q) ()T!4%8AZ=L<M=
M!,!>&XOX%A\Z*')_\]U+AE>E&XYG+P$R3^[8I:51I6Y\6&+73+Z'N[-E_@\
M1,M! UA8QDE2LI*63!J0WO6TO" O?*GJD_=$)SS'A&P !B2+S@H#NK]%[DH!
MU&.*Q@*6 )T2*D"J)8!8%R [L@L!/JR!!VRP@!: X 9@M"0RDZG,%BJ%?#$1
M@(X2%:D"9E)&@.S:Z4C6)SI.IP!ZV1)9(.=# AC   ]HE@B,E:S2S(8 SB--
MGPHU /* TT=&W"  :E #%BB@!9$\YC(#*M"!VHR'U9G.\794&E9F,G/-@:-
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ME0#FB<D$D;<C%1GF9#<9 0%2D $5K$!$"/H "\0$D=BYE+?N?2]\H^0B0 9
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g306472g44a18.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g306472g44a18.gif
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MSFN$K6NEO8R4K924G-[W_VNMUG.MSIR<I6N$M0
M
M
M
M                     "P     I@*)   (_@ !*"C  $ ,"A4J4*A!(0
M @4&(!@@0 & !00^'!!1!@"" P8<(E@ X "  0L.!""( $$ EP "3 ! LV"
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M17@N<4L!&<:LDOB%1.NZB0"E8BN^'8M9 '.6N/XE%7HEIT@).MK18M(DGDS
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M?^)RY +0OK2ZAF$(:Q@>(W<; >"34028W!53_I_*_55V "=]G6[ 'QZ+[<0
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M4 ,UL*&^TG58(8S>Q*6Y8CLF(0,RD $R4(/.>E#+%%*05XIB"4O*]H"[<VN
MU(OXE$.<(T!LY2\L,P#JR*NBV1,F(;@J(5%'R%Y @5>?DV8F8C?L9C9L]2[
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MG%EK#Y\=]/7GWX631FYLWC)QHO,QYT:X^< $EQ-:2CZ)-INNDFRSXL9S+2G
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MXUT-,+(6UMC$*6FK<I0T640 'M"(,4@).3@:'S :SA,!(V@,J6NO7T.$#7@
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MFQ)8@JR+)@(HUJ4;& 10@9<8&B/@&CS(N@!#&J> #ZWM(I*U:Q-C"ZBHU\Q
MD\2"LL2[?2NVC*D-,= X$$M9U".E%\MHDQLC0=[AB[5 %*O2M"^5L6,'B (%
M A1   !   4'%00XB""!P8,$#AYLB.! PP,5#T"T"*"  0!*+%B( @#!EQ<6
M7APXP.# "Y8%>+ (463"APH55C+XT. #@)8!.KRH( / ! @U14R8($$""Q$
M&DP P**%@P\B6!1@_D"319 /&T9\L,"BT8U-7 L@_%A2YPH6"3EPH!E"R(,@
M!E4V=$&2Q0<0"%\@.O#!2 @690),4(' @J>@=F$(I/HBU(0&/"P<G*"Q@ 4E
M!EFT0CB0(H $"B2\ .#AJ<V#+EA<#?H@L0N$9H56> %5A(D2-!$0V"KP8-:G
M7:.8!0%AP^T=NP H^,3"X(,B'W:$>("EP@^S+G2.W,'D _K$/):44 D!!-VM
M++(@Z,WR@TN2![*FOW !(FP%?)"5"7P!X%<1(B" 0 L6=*=00P<1P8(NNG!
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M:E:<<MY$[H<0@^2/+<5;X 47Q"@","<T%Z,-#ZR0 !6H8#@$>%9B:,,"LX0
M2BH+2@G^LD3:F,4"P%L)GIX6 PK,!CU;^< 62)* G%2@*7S@0P$:$ <K F\"
MC&&!W29 .2^@AP51@!U23H  HB E>A; !? :\I2/Q.0O9EFB!:PT.R;(_DP!
M _$+ V;" HU\L&:@8<$8,$"_*VED 4])@%,D4)7DS28$V2J! RPP _:=K7@)
M\,U$"H(!VH@ 2#'SU0@8P)I(8FQ<"2@( 4ZFLR&<A""&64D $C"[DAR$)A8)
M  TJ$ (Z,&$64SSD$D/ I@PI" !;"8$(+HB:0!U@D"ZC0$-68 $1E,$MD9E
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M *VP0+:R98$OU& G2J!.5WP#@"<!8 Q #,,+2O  "X98 D1:W4$2P%46W @
M9[-K0R*)B/:.A 48\-:$0(LG:4:A!"& S&SW&P479.>-A#A)7((@@D$=\"D<
MF2H%MDB_8H&3+22YX O<0#P ?&A^+##"\!"P )VLYA8((>X<[N"&#@%* BUU
M\ H:L-/'K$ @+P@# *QT5  0H:(VQB@%/,2! K] %NJJS3T!,#N5(>!D)[4
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M+SF<I,""!?S=]Q'15DR !OA%5E@<R]C9W%D1)0U*%S31@;"  QQ !5! 4\!
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M22P;GE  ?BP(*J#"M5U) FC$T5A933+!4_0$H11$#@&A8%+)@NA$#;S/L%V
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M9 5 /\20. !R_$U6,$#:Y'5J+-P!I(#,"-X&#2!2'$H#  ]N 6 (HN-.\E\
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M@!)X,P%A&3>N204">"O@@P%.< N*"=1<+:F]AA3RO842<.NJ"FCHXXY6>7-
M"CL_\/"WLPX04;7C%LC@J@*\+4 %(3.0 3( *  @AO04^(F^FN@3$<G\IKJ-
M %_M1%B@@X6*:RKZ5CRA3A(!^&."/$3)%VZD_9J Y[(,H."$)18"((,"3M!R
MHXT(<N WS0XHH808_JS;D_&<IG.XSHU8?-CP#!8(X#BO)QAA ;@G$ GG#P;B
M(*P$#S@A/I/HBZ\!AGITE-&# = ,N/H.^'T."B1W* $'.N9.@]LCWPNJA>"F
M<34E<[,3 !F W)>D=L\E2""%@F2(P>D6@C2&.?9RO6CZ4*N @+419$L%!@:
M_@,;&AF%@]S]KL%.P"HW@(Z%16(#8=^)3 0 $I"@.48(04M>, />?, !#WB
M62 0 I7\Q"RH8@$&$%"!%3UG(+?!DWT*)Q0*8( %J%K-!TJ@DA 4@3XF% \#
M7G 1"^R =<%9R,82(",A=0Q>8<%)4[C7K_0,18"Y(8  ]R46 I3,>M]Z_@R\
MKD(5]W3/6QTC"&.NTB".$66+=XD/2=@6GZ(@8&.A<XH7$1*9C8E% $/Q8GS,
M]9XEO64MY9I)Y@18F(/53T[ONZ,!?,([[Q&FC68<6)P6L*1O[24KBJ1)UP;#
MDX%-Y4S.\Z(4'TF0!=3)B0AP2O<"Q!:UK,5@[?ID9([(FG.U<2ASI D;M320
MFYRK7 =;HD.(^$3"$(5<532E4-:V+H]YT0!T&:;#UH6BH5"E8Z:\4[\:=L2#
MA6X@I&3*5 A0 *GD!HNF9(TW]50G3M;$E 9S3](\V;U"#BPH[5)+G!8Y2^JU
MLF-U"H DUP(82T;EGD*RR544<! %R$N!#%2!_A"$\(,66F""!X" &!8" 0A<
MQ'L30 1&++"3!IS.30 P8>9F!I\*( ""B:#/!W:@$AC6D$H,2$%,925!/4'%
M/N,2B"WI.*XP%F::;!3G0;183;8<="!!84LFJZ< IYK280DIHUL(8,1NQFBJ
M<7I,&JER%@$PSI-,(2510DD0J#J$5W/D9J?<\ST"W)-=352B6S*9$#1ZD20Y
M$R<^@2*5@XT'L'=Y#(K8&)OO->5="<@D,>G*26W.9 $DH9=2LJ)5QO+J7 %U
MCUA^(DPOYDPHC/UJ !S[+7*ME2U6Z6Q/"&,GPBI LW%Z'UTYF#9YHL>U"5GL
M3"H9R3_.Y(F7;1C%_@@#6W-EJC!V0JZ6'LG&H4313EF);4()X%AWJ16U=*7L
M,*N7$U^Z$JH+".U?V97:SA(6JO]DY$A^*TV"I-9[G;T*:@O;@#!)2P(B$ %N
M"#"IEUC !UIS0 A0Q0,Z &@^6Q2*ZG*BL@/@H 4;G)X;,,(#!S1J N\I@0=9
ML($'-(<ZORE+Q82:FS[NY)X"-.01&6( JSA1+-3]J5V]*)@X+41S98Q,)AFJ
M6B7II)*# <S:.F88QO+EI]X,@ !Q7% &\.F(2=SB^S!#72HKU:>$L<J+_^A*
M(;/3/5*IY6ZE:<?!9C>@KDIQ2 8+6/C\5)<5 RHT._:8LPSF*>^)K6LW_HEB
MW?;2G$+Y;#43:\=5NEG(4S8N>:-X "/"!ZHZ7@MF_$B3I2AS 6L$Z@&LFV>"
MA)->$INK-O$;QMP,X":1C>O%B/M)0P^U8=.4]5-@O!,P-R7(J+R8F1.;R3KU
MA'=4H6^:4XSCG41Q8 SY  ,RD1()S) T)LK#)U9E :QI%,1.JYV/8[21&;7D
M(D0:B$=80(4<F.#;#-A!@GD@ @B0>"$*\-Q5SI+J&"V671M1Y+)C^][[2#6;
M#IL)5\2ERZ/&\5L HV0N@<FQ+,U$7O&9L5IQR6(A[W;&CUQ2N=0"%6=N:I@.
M;MA1E2)*<0?,K-93SVYW26M\(A.?4*,Y.<42_DBD#(:UL!2+P$C=L.W!!2P"
M?^4?^SC*Q#+E?2P>3R(S"50O-I& W23)KMDIFR-J5IEG1?1(T!N71:IE -P\
M8F@#_LJJWY*=:9YU]4!;[("?B]5LZ6+#2JM:=L9RV76RY2H+\U>P_Q,^!>!F
M*K&[W+13-Y-KMWFF<W87G3<U[;&424*L^CW '$TU)>Q="4*@P1>X8 45<(K#
M5("JWDP&#!=@213F5P$O^&B+*2B!"(S@"56Q0#,%6%8.WW;?3.1PVB5P"^6F
MI!B;0$3K0]P(?NO41!TO):@"09I W.),MM0ZXC1N;A8-^55##T5@ NV)FCM&
M;'/IA,RUI(E9#IL0_K.4J\]\.8M=<U*5V-X<(0+1F,6 192FJV,2PK&0B_WL
MB("(:7L 0ZWZPB;B0B>([=#JJ[E6";^LZS',HK0.*C!&[F R#2>R!(\.1BXX
MAF-L0F?(B""HCXC4;##F(E-V*CXT4#(FL'MNKN&$PK'&@V+&#SVP;XQBA/OZ
M!9Q^:L] ">\XD ,;D*@H<)'<:29BT )OZ0'+8OF88@!^PHAB,(_JJP=!T([Z
M;_O.@B[V;.\.QF"":.G"$"F.Z"P8D"E02\TB4&**BET2\']$R0HUL"&^!]?>
M+BP>2=*X8P1^ E(^( 5X@ ARB 5X@ ,,9"APZ 5"X .LPP$.0 (NH"6:_J,"
M9(""MN@#'H -0B#;7( W/F,,6N@%=B(#%(:_+&@A_(< *$#"8@0X'$1(%$
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MZM5NKC7_[>B6BT_<HHG8B<S B<ZE;H8)PR&-]0Y]$28_2SWLR#YZCL[Q_@I
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M4Y#P(P-$G,"FY1JU/N@".I@"]'(H@DJ@"&[ !")C6FB?]@G"!#Z  D@  AP
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M +M;0+][0VE,OZ 6 TY+7/("3DA"&-&Q)/KG'Y%P.%UR'I+0!K7!N15@/@Y
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M+\  'Q  #0;P3P "#)H($E8;K5$$$  =<S 'V1($(6 !/D"(#_  U@40 0
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M A(8@:P7"@DP!!Y$@.VL&<Y:CX(:>D.+C0<N^U"$UV)#ZP5#/.I*Q1?$V "
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M ;5(@0.XG\:KH;>BKM(!&ZPS%J*(D_+I'5_JK\M*DYZ9J@<[J@I!G;<##XL
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M2(!)2;!LX8ENL;74*:VCHID78ZN3\9D)*(&<T:D"*@(Y")4]+*X\7$9G7#U
M- PIVJ2& *LOR8 &N)CO>K(AHXP[^0!5LH"P_E$!!P!'"_"(#R@!;E0ERE"
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M/0P !GA"QI !FW*(_I8P0;_JC>W"&(S;N>KH&ZXP@);LPM@S'_8I".<KB-X
M&<BT$*1KCPESG8"K*@E;G6=!%BO;M)/(B <#LHLD#BS,2][+'L/TQ>)H !,
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M8$/%J.BZK\$)MYR0!H(*Y[*2X5&*JS,.EBC9A?D UWL 2+-7G_U91+F2KG
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M!0 I<  +^(%G&S6;:+RH%1&;8 $(D-- #A$6_OB %.B-D[. *>A@]TB(N2N
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MI*4(BM<[GWP27S^JT.P<R_MI 1=P?O^'4(  (## @0 "!1XH6!! P@D#!28
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JE6:OO.9*^#.;FTI9JFQ]E9M(UP32  <@ABD/@$ $I.? !T(P@C(*"  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
